Colon Cancer with High TMB and POLE Mutation

Needs Statement

Medical oncologists and hematologists, geneticists, and all other healthcare professionals and trainees who treat patients with cancer need to receive regular updates on recent advances in tumor sequencing, identification of actionable mutations, and targeted treatments of tumor pathways. The tumor board aims to bridge the current practice gap between the tumor sequencing information now readily available to clinicians and the potential for on-label or off-label targeted therapies especially through clinical trial referrals. The goal of the tumor board is to advance the knowledge of learners regarding the application and interpretation of next-generation sequencing results to ultimately improve patient care.

Educational Objectives

At the conclusion of the sessions, the participants should be able to:

• Interpret molecular pathology reports and identify recommended guideline-supported therapy.
• Assess the literature for promising off-label therapies or clinical trial avenues.
• Recognize the strengths and limitations of different facets of molecular testing in oncology (e.g., liquid vs. solid biopsies, RNA-based vs. DNA-based testing).

Target Audience

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.